Difference between revisions of "Macasoi 2020 Oncol Rep"
Line 6: | Line 6: | ||
|journal=Oncol Rep | |journal=Oncol Rep | ||
|abstract=Cancer remains a major health problem worldwide due to its high mortality rate. New therapeutic options highlight the importance of discovering new compounds that target the tumor microenvironment, interrupt angiogenesis and act selectively. The present study assessed the antitumor effect and investigated the mechanism of action of a rhodamine Bāconjugated oleanolic acid derivative (RhodOA). Consequently, the compound was tested on different human tumor cell lines (A375 melanoma, A549 lung adenocarcinoma and MDAāMBā231 breast adenocarcinoma) and on a nonātumor cell line HaCaT human keratinocyte. RhodOA produced a doseādependent decrease in tumor cell viability especially in the melanoma cells while affecting the keratinocytes less. In melanoma cells, RhodOA reduced cell migration and produced condensation of cell nuclei and of actin fibers. Furthermore, an impairment in melanoma cell mitochondrial function was observed, while the mitochondrial function of keratinocytes was left intact. In the ''in ovo'' chorioallantoic membrane model, RhodOA elicited antiangiogenic effect, without showing irritation effect on the membrane. The study provides information on the selective antitumor effect of the derivative and its ability to inhibit cellular respiration, therefore RhodOA can be classified as āMITOCANā. | |abstract=Cancer remains a major health problem worldwide due to its high mortality rate. New therapeutic options highlight the importance of discovering new compounds that target the tumor microenvironment, interrupt angiogenesis and act selectively. The present study assessed the antitumor effect and investigated the mechanism of action of a rhodamine Bāconjugated oleanolic acid derivative (RhodOA). Consequently, the compound was tested on different human tumor cell lines (A375 melanoma, A549 lung adenocarcinoma and MDAāMBā231 breast adenocarcinoma) and on a nonātumor cell line HaCaT human keratinocyte. RhodOA produced a doseādependent decrease in tumor cell viability especially in the melanoma cells while affecting the keratinocytes less. In melanoma cells, RhodOA reduced cell migration and produced condensation of cell nuclei and of actin fibers. Furthermore, an impairment in melanoma cell mitochondrial function was observed, while the mitochondrial function of keratinocytes was left intact. In the ''in ovo'' chorioallantoic membrane model, RhodOA elicited antiangiogenic effect, without showing irritation effect on the membrane. The study provides information on the selective antitumor effect of the derivative and its ability to inhibit cellular respiration, therefore RhodOA can be classified as āMITOCANā. | ||
|keywords=Rhodamine Bāoleanolic acid derivative bioconjugate, Melanoma, Mitochondrial function, Chorioalantoid membrane, Immunofluorescence, Cytotoxicity | |||
|editor=[[Plangger M]] | |editor=[[Plangger M]] | ||
|mipnetlab=RO Timisoara Muntean DM | |||
}} | }} | ||
{{Labeling | {{Labeling |
Revision as of 22:10, 16 July 2020
MacaČoi I, Pavel IZ, MoacÄ AE, Avram S, David LV, Coricovac D, Mioc A, Spandidos DA, Tsatsakis A, Čoica C, DumitraČcu V, Dehelean C (2020) Mechanistic investigations of antitumor activity of a Rhodamine Bāoleanolic acid derivative bioconjugate. Oncol Rep [Epub ahead of print]. |
Ā» Open Access
Macasoi Ioana, Pavel Ioana Zinuca, Moaca Alina Elena, Avram Stefana, David Laurentiu Vlad, Coricovac Dorina, Mioc Alexandra, Spandidos Demetrios A, Tsatsakis Aristidis, Soica Codruta, Dumitrascu Victor, Dehelean Cristina (2020) Oncol Rep
Abstract: Cancer remains a major health problem worldwide due to its high mortality rate. New therapeutic options highlight the importance of discovering new compounds that target the tumor microenvironment, interrupt angiogenesis and act selectively. The present study assessed the antitumor effect and investigated the mechanism of action of a rhodamine Bāconjugated oleanolic acid derivative (RhodOA). Consequently, the compound was tested on different human tumor cell lines (A375 melanoma, A549 lung adenocarcinoma and MDAāMBā231 breast adenocarcinoma) and on a nonātumor cell line HaCaT human keratinocyte. RhodOA produced a doseādependent decrease in tumor cell viability especially in the melanoma cells while affecting the keratinocytes less. In melanoma cells, RhodOA reduced cell migration and produced condensation of cell nuclei and of actin fibers. Furthermore, an impairment in melanoma cell mitochondrial function was observed, while the mitochondrial function of keratinocytes was left intact. In the in ovo chorioallantoic membrane model, RhodOA elicited antiangiogenic effect, without showing irritation effect on the membrane. The study provides information on the selective antitumor effect of the derivative and its ability to inhibit cellular respiration, therefore RhodOA can be classified as āMITOCANā. ā¢ Keywords: Rhodamine Bāoleanolic acid derivative bioconjugate, Melanoma, Mitochondrial function, Chorioalantoid membrane, Immunofluorescence, Cytotoxicity ā¢ Bioblast editor: Plangger M ā¢ O2k-Network Lab: RO Timisoara Muntean DM
Labels: MiParea: Respiration, Pharmacology;toxicology
Pathology: Cancer
Organism: Human Tissue;cell: Endothelial;epithelial;mesothelial cell Preparation: Permeabilized cells, Intact cells
Coupling state: LEAK, ROUTINE, OXPHOS, ET
Pathway: N, S, NS, ROX
HRR: Oxygraph-2k
2020-07